Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Legal and Finance
  • Published:

Strategies for managing risk in equity

Nature Biotechnology volume 20, pages BE57–BE60 (2002)Cite this article

Founders, senior executives, and venture capitalists often own restricted equity in startup companies, which they must manage proactively to minimize the risk and maximize value, says C. Mark Tang.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

© Bob Crimi

Author information

Author notes

  1. C. Mark Tang has followed and invested in the biotechnology industry for over a decade. He has been a biotechnology analyst, venture capitalist, wealth-management financial adviser, and publisher of the Bio/Medical Technology Stock Newsletter. Tang currently works for Morgan Stanley Dean Witter, New York. The opinions expressed in the article are the personal opinions of the author.

Authors
  1. C. Mark Tang
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tang, C. Strategies for managing risk in equity. Nat Biotechnol 20 (Suppl 6), BE57–BE60 (2002). https://doi.org/10.1038/nbt0602supp-BE57

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0602supp-BE57

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing